The Use of Statins for Myocardial Death Prevention

Phase 4

Completed

• Conditions: Myocardial Infarction
• Interventions: Drug: Atorvastatin

• Registration Number: NCT00772564
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2008-10-11
• Study First Submitted QC: 2008-10-14
• Study First Posted: 2008-10-15
• Primary Completion: 2010-06
• Study Completion: 2010-08
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-25
• Last Update Posted: 2012-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

Exclusion Criteria

1. The impossibility to give the required informed consent.
2. Known allergy to Atorvastatin.
3. Base line serum creatinine of 1.4 mg/dL.
4. Killip Classification 3 and 4.
5. Persisting vomiting.
6. History of previous liver disease.
7. History of previous muscle disease or rabdomyolisis.
8. Treated already with high dose atorvastatin
9. Non Compliance.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Atorvastatin 10 mg	Atorvastatin	-
Atorvastatin 80 mg	Atorvastatin	-

Primary Outcome Measures

Name	Time	Method
Heart EcoCardiography and specific laboratory tests	Base line, second day and 60 days after myocardial infarction

Trial Locations

Locations (1)

Rambam Health Care Campus; 🇮🇱 Haifa, Israel